$173 Million is the total value of JNE Partners LLP's 13 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| WALDW | Exit | WALDENCAST ACQUISITION CORP*w exp 03/11/202 | $0 | – | -333,333 | -100.0% | -0.16% | – |
| WALD | Exit | WALDENCAST ACQUISITION CORP | $0 | – | -1,000,000 | -100.0% | -6.43% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| NOVAGOLD RES INC | 16 | Q3 2023 | 34.9% |
| AMERCO | 11 | Q3 2022 | 40.0% |
| ELLIOTT OPPORTUNITY II CORP | 9 | Q2 2023 | 19.8% |
| COMCAST CORP NEW | 8 | Q1 2022 | 23.5% |
| ORION BIOTECH OPPORTUNTES CO | 8 | Q1 2023 | 11.1% |
| MSD ACQUISITION CORP | 8 | Q4 2022 | 11.1% |
| LIBERTY MEDIA CORP DEL | 8 | Q2 2023 | 13.9% |
| ROCKET INTERNET GRWT OPRT CO | 8 | Q4 2022 | 3.2% |
| KKR ACQUISITION HOLDING I CO | 7 | Q3 2022 | 1.7% |
| MICRON TECHNOLOGY INC | 5 | Q3 2023 | 56.9% |
View JNE Partners LLP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Prevail Therapeutics Inc. | January 29, 2021 | ? | ? |
View JNE Partners LLP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-15 |
View JNE Partners LLP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.